522 related articles for article (PubMed ID: 32973794)
21. The Emerging Role of CD8
Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
Front Immunol; 2018; 9():1904. PubMed ID: 30158938
[TBL] [Abstract][Full Text] [Related]
22. Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully.
Lin B; Du L; Li H; Zhu X; Cui L; Li X
Biomed Pharmacother; 2020 Dec; 132():110873. PubMed ID: 33068926
[TBL] [Abstract][Full Text] [Related]
23. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.
Chacon JA; Sarnaik AA; Chen JQ; Creasy C; Kale C; Robinson J; Weber J; Hwu P; Pilon-Thomas S; Radvanyi L
Clin Cancer Res; 2015 Feb; 21(3):611-21. PubMed ID: 25472998
[TBL] [Abstract][Full Text] [Related]
24. Activation of T lymphocytes for the adoptive immunotherapy of cancer.
Sussman JJ; Shu S; Sondak VK; Chang AE
Ann Surg Oncol; 1994 Jul; 1(4):296-306. PubMed ID: 7850528
[TBL] [Abstract][Full Text] [Related]
25. Signaling defects in anti-tumor T cells.
Frey AB; Monu N
Immunol Rev; 2008 Apr; 222():192-205. PubMed ID: 18364003
[TBL] [Abstract][Full Text] [Related]
26. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Ikeda H
Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
[TBL] [Abstract][Full Text] [Related]
27. Regulation of Memory CD8+ T Cell Differentiation by MicroRNAs.
Zhang Z; Zhang C; Li F; Zhang B; Zhang Y
Cell Physiol Biochem; 2018; 47(6):2187-2198. PubMed ID: 30011396
[TBL] [Abstract][Full Text] [Related]
28. Cellular immunotherapy of cancer: an overview and future directions.
Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S
Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516
[TBL] [Abstract][Full Text] [Related]
29. Resident Memory-Like Tumor-Infiltrating Lymphocytes (TIL
Smazynski J; Webb JR
Front Immunol; 2018; 9():1741. PubMed ID: 30093907
[TBL] [Abstract][Full Text] [Related]
30. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma.
Noonan KA; Huff CA; Davis J; Lemas MV; Fiorino S; Bitzan J; Ferguson A; Emerling A; Luznik L; Matsui W; Powell J; Fuchs E; Rosner GL; Epstein C; Rudraraju L; Ambinder RF; Jones RJ; Pardoll D; Borrello I
Sci Transl Med; 2015 May; 7(288):288ra78. PubMed ID: 25995224
[TBL] [Abstract][Full Text] [Related]
31. Enhancing adoptive T cell immunotherapy with microRNA therapeutics.
Ji Y; Hocker JD; Gattinoni L
Semin Immunol; 2016 Feb; 28(1):45-53. PubMed ID: 26710685
[TBL] [Abstract][Full Text] [Related]
32. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
33. Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
Weigelin B; BolaƱos E; Rodriguez-Ruiz ME; Martinez-Forero I; Friedl P; Melero I
Cancer Immunol Immunother; 2016 May; 65(5):493-7. PubMed ID: 26970765
[TBL] [Abstract][Full Text] [Related]
34. Metabolic reprograming of anti-tumor immunity.
Sukumar M; Kishton RJ; Restifo NP
Curr Opin Immunol; 2017 Jun; 46():14-22. PubMed ID: 28412583
[TBL] [Abstract][Full Text] [Related]
35. Metabolic Barriers to T Cell Function in Tumors.
Sugiura A; Rathmell JC
J Immunol; 2018 Jan; 200(2):400-407. PubMed ID: 29311381
[TBL] [Abstract][Full Text] [Related]
36. MR1-restricted T cells: the new dawn of cancer immunotherapy.
Wang Z; Wang M; Chen J; Zhang L; Zhang L; Yu L
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33185693
[TBL] [Abstract][Full Text] [Related]
37. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.
Li H; Zhao Y
Protein Cell; 2017 Aug; 8(8):573-589. PubMed ID: 28434147
[TBL] [Abstract][Full Text] [Related]
38. Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy.
Innamarato P; Kodumudi K; Asby S; Schachner B; Hall M; Mackay A; Wiener D; Beatty M; Nagle L; Creelan BC; Sarnaik AA; Pilon-Thomas S
Mol Ther; 2020 Oct; 28(10):2252-2270. PubMed ID: 32615068
[TBL] [Abstract][Full Text] [Related]
39. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
[TBL] [Abstract][Full Text] [Related]
40. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches.
Klein K; He K; Younes AI; Barsoumian HB; Chen D; Ozgen T; Mosaffa S; Patel RR; Gu M; Novaes J; Narayanan A; Cortez MA; Welsh JW
Front Immunol; 2020; 11():573326. PubMed ID: 33178201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]